A drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists.
| Member | Definition | Class |
|---|
| (S)-carbinoxamine maleate | The maleic acid salt of (S)-carbinoxamine. | (S)-carbinoxamine maleate |
| 4-diphenylacetoxy-1,1-dimethylpiperidinium | A quaternary ammonium salt obtained by formal methylation of the tertiary amino function of 4-diphenylacetoxy-N-methylpiperidine. | 4-DAMP(1+) |
| 4-diphenylacetoxy-n-methylpiperidine methiodide | A quaternary ammonium salt obtained by combining equimolar amounts of 4-diphenylacetoxy-N-methylpiperidine and iodomethane. | 4-DAMP methiodide |
| aclidinium bromide | A quaternary ammonium salt that is the bromide salt of aclidinium. A muscarinic acetylcholine M3 receptor antagonist, for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). | aclidinium bromide |
| benzquinamide | | benzquinamide |
| biperiden | A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease. | biperiden |
| biperiden hydrochloride | The hydrochloride salt of biperiden. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease. | biperiden hydrochloride |
| bromodiphenhydramine | A tertiary amino compound that is the 4-bromobenzhydryl ether of 2-(dimethylamino)ethanol. An antihistamine with antimicrobial properties, it is used in the control of cutaneous allergies. | bromazine |
| carbinoxamine | An organochlorine compound that is 2-(4-chlorobenzyl)pyridine in which one of the benzylic hydrogens is substituted by 2-(dimethylamino)ethoxy group. It is an ethanolamine-type antihistamine, used as its maleate salt for treating hay fever, as well as mild cases of Parkinson's disease. | carbinoxamine |
| carbinoxamine maleate | The maleic acid salt of carbinoxamine. An ethanolamine-type antihistamine, used for treating hay fever, as well as mild cases of Parkinson's disease. | carbinoxamine maleate |
| cinnarizine | | cinnarizine |
| clemastine | 2-[(2R)-1-Methylpyrrolidin-2-yl]ethanol in which the hydrogen of the hydroxy group is substituted by a 1-(4-chlorophenyl)-1-phenylethyl group (R configuration). An antihistamine with antimuscarinic and moderate sedative properties, it is used as its fumarate salt for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions. | clemastine |
| clemastine fumarate | The fumaric acid salt of clemastine. An antihistamine with antimuscarinic and moderate sedative properties, it is used for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions. | clemastine fumarate |
| clozapine | A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia. | clozapine |
| cyclopentolate | A carboxylic ester resulting from the formal condensation of (1-hydroxycyclopentyl)(phenyl)acetic acid with N,N-dimethylethanolamine. A tertiary amine antimuscarinic with actions similar to atropine, it is used as its hydrochloride salt to produce mydriasis (excessive dilation of the pupil) and cycloplegia (paralysis of the ciliary muscle of the eye) for opthalmic diagnostic procedures. It acts more quickly than atropine and has a shorter duration of action. | cyclopentolate |
| cycrimine | A member of the class of piperidines that is 3-(piperidin-1-yl)propan-1-ol in which one of the hydrogen atoms at the 1-position is substituted by cyclopentyl, and the other is substituted by phenyl. A central anticholinergic, it is used as its hydrochloride salt in the management and treatment of Parkinson's disease. | cycrimine |
| darifenacin | 2-[(3S)-1-Ethylpyrrolidin-3-yl]-2,2-diphenylacetamide in which one of the hydrogens at the 2-position of the ethyl group is substituted by a 2,3-dihydro-1-benzofuran-5-yl group. It is a selective antagonist for the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions, and is used as the hydrobromide salt in the management of urinary incontinence. | darifenacin |
| darifenacin hydrobromide | The hydrobromide salt of darifenacin. A selective antagonist for the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions, it is used in the management of urinary incontinence. | darifenacin hydrobromide |
| dicyclomine | The ester resulting from the formal condensation of 1-cyclohexylcyclohexanecarboxylic acid with 2-(diethylamino)ethanol. An anticholinergic, it is used as the hydrochloride to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome. | dicyclomine |
| dicyclomine hydrochloride | The hydrochloride salt of dicyclomine. An anticholinergic, it is used to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome. | dicyclomine hydrochloride |
| diphemanil methylsulfate | The alkene resulting from the formal Wittig olefination of benzophenone and 1,1-dimethyl-4-bromopiperidinium methylsulfate. A quaternary ammonium anticholinergic, it binds muscarinic acetycholine receptors and thereby decreases secretory excretion of stomach acids, saliva and sweat, It is used topically in the treatment of hyperhidorsis (excessive sweating). | diphemanil methylsulfate |
| diphenhydramine | An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug. | diphenhydramine |
| diphenhydramine hydrochloride | The hydrochloride salt of diphenhydramine. | diphenhydramine hydrochloride |
| flavoxate | A carboxylic ester resulting from the formal condensation of 3-methylflavone-8-carboxylic acid with 2-(1-piperidinyl)ethanol. | flavoxate |
| flavoxate hydrochloride | The hydrochloride salt of flavoxate. | flavoxate hydrochloride |
| himbacine | A piperidine alkaloid that is decahydronaphtho[2,3-c]furan-1(3H)-one substituted by a methyl group at position 3 and a 2-[(2R,6S)-1,6-dimethylpiperidin-2-yl]ethenyl group at position 4. It has been isolated from the bark of Australian magnolias. | himbacine |
| methixene | | metixene |
| methoctramine | A tetramine that is N,N'-bis(6-aminohexyl)octane-1,8-diamine where the primary amino groups both carry 2-methoxybenzyl substituents. | methoctramine |
| methoctramine | A hydrochloride obtained by combining methoctramine with four molar equivalents of hydrochloric acid. | methoctramine tetrahydrochloride |
| nsc 23766 | An aminopyrimidine that is 6-methylpyrimidine-2,4-diamine in which the amino groups at positions 2 and 4 are substituted by 5-(diethylamino)pentan-2-yl and 4-amino-2-methylquinolin-6-yl groups respectively. An inhibitor of the signalling G-protein known as RAC1 (Ras-related C3 botulinum toxin substrate 1). | NSC 23766 |
| nsc 23766 | A hydrochloride resulting from the formal reaction of NSC 23766 with 3 mol eq. of hydrogen chloride. An inhibitor of the signalling G-protein known as RAC1 (Ras-related C3 botulinum toxin substrate 1). | NSC 23766 trihydrochloride |
| octotropine methylbromide | A quaternary ammonium salt resulting from the reaction of the amino group of anisotropine with methyl bromide. | anisotropine methylbromide |
| olanzapine | A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4. | olanzapine |
| orphenadrine | A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol. | orphenadrine |
| orphenadrine citrate | A citrate salt which comprises equimolar amounts of orphenadrine and citric acid. | orphenadrine citrate |
| orphenadrine hydrochloride | A hydrochloride comprising equimolar amounts of ophenadrine and hydrogen chloride. | orphenadrine hydrochloride |
| oxybutynin | A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder. | 4-(diethylamino)but-2-yn-1-ol; oxybutynin |
| pirenzepine | | pirenzepine |
| pizotyline | A benzocycloheptathiophene that is 9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thiophene 4-ylidene)-1-methylpiperidine which is joined from the 4 position to the 4 position of an N-methylpiperidine moiety by a double bond. It is a sedating antihistamine, with strong serotonin antagonist and weak antimuscarinic activity. It is generally used as the malate salt for the treatment of migraine and the prevention of headache attacks during cluster periods. | pizotifen |
| procyclidine | A tertiary alcohol that consists of propan-1-ol substituted by a cyclohexyl and a phenyl group at position 1 and a pyrrolidin-1-yl group at position 3. | procyclidine |
| profenamine | A member of the class of phenothiazines that is phenothiazine in which the hydrogen attached to the nitrogen is substituted by a 2-(diethylamino)propyl group. An antimuscarinic, it is used as the hydrochloride for the symptomatic treatment of Parkinson's disease. | profenamine |
| profenamine hydrochloride | The monohydrochloride salt of profenamine. An antimuscarinic, it is used for the symptomatic treatment of Parkinson's disease. | profenamine hydrochloride |
| promazine | A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position. | promazine |
| propiomazine | A member of the class of phenothiazines that is 10H-phenothiazine substituted by a 2-(dimethylamino)propyl group at nitrogen atom and a propanoyl group at position 2. | propiomazine |
| propyromazine | An organic bromide salt of propyromazine. It is a muscarinic antagonist which has antispasmodic potential. | propyromazine bromide |
| quinidine | A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy. | quinidine |
| thiethylperazine | A member of the class of phenothiazines that is perazine substituted by a ethylsulfanyl group at position 2. | thiethylperazine |
| tiquizium bromide | A organic bromide salt of tiquizium. It is an antispasmodic drug used for the treatment of convulsion and hypermobility in gastritis, gastric ulcer, duodenal ulcer, enteritis, irritable bowel syndrome, gallbladder disease, biliary tract disease and urolithiasis. | tiquizium bromide |
| tolterodine | | tolterodine |
| tramadol | A 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol in which both stereocentres have R-configuration; the (R,R)-enantiomer of the racemic opioid analgesic tramadol, it exhibits ten-fold higher analgesic potency than the (S,S)-enantiomer. | (R,R)-tramadol |
| tramadol hydrochloride | A hydrochloride resulting from the reaction of (R,R)-tramadol with 1 molar equivalent of hydrogen chloride; the (R,R)-enantiomer of the racemic opioid analgesic tramadol hydrochloride, it exhibits ten-fold higher analgesic potency than the (S,S)-enantiomer. | (R,R)-tramadol hydrochloride |
| tridihexethyl | | tridihexethyl |
| ziprasidone | A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms. | ziprasidone |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 17.7828 | 1 | 1 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| 67.9K protein | Vaccinia virus | Potency | 19.0919 | 2 | 2 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 20.3645 | 2 | 12 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 21.9865 | 1 | 4 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 3.4419 | 1 | 3 |
| AR protein | Homo sapiens (human) | Potency | 20.9819 | 9 | 40 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 28.8727 | 2 | 6 |
| arylsulfatase A | Homo sapiens (human) | Potency | 19.0902 | 1 | 6 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 9.0174 | 2 | 5 |
| Ataxin-2 | Homo sapiens (human) | Potency | 25.0647 | 2 | 8 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 11.9845 | 3 | 7 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 21.2658 | 2 | 3 |
| atrial natriuretic peptide receptor 2 precursor | Homo sapiens (human) | Potency | 8.3903 | 1 | 3 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 44.0751 | 2 | 8 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 72.1043 | 1 | 4 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 33.4915 | 1 | 3 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 29.8493 | 1 | 1 |
| caspase-3 | Homo sapiens (human) | Potency | 33.4915 | 1 | 3 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 29.8493 | 1 | 1 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 19.4382 | 2 | 16 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 14.7893 | 2 | 6 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 20.3652 | 1 | 4 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 27.8298 | 2 | 2 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 144.7410 | 1 | 4 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 39.8107 | 1 | 1 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 10.0000 | 1 | 1 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 26.5272 | 2 | 5 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 44.2452 | 1 | 3 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 45.5536 | 1 | 5 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 10.5772 | 1 | 5 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 26.5272 | 2 | 5 |
| chaperonin-containing TCP-1 beta subunit homolog | Homo sapiens (human) | Potency | 15.8489 | 1 | 1 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 42.9989 | 2 | 9 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 13.0441 | 1 | 5 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 29.7969 | 1 | 4 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 15.3699 | 1 | 7 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 6.5155 | 1 | 20 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 12.5252 | 1 | 15 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 10.8633 | 2 | 28 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 13.4983 | 2 | 22 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 16.9822 | 1 | 5 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 5.4660 | 3 | 11 |
| D(1A) dopamine receptor | Sus scrofa (pig) | Potency | 14.6892 | 1 | 1 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 16.2710 | 1 | 2 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 59.6218 | 1 | 2 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 70.3519 | 1 | 3 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 12.9551 | 1 | 3 |
| dopamine D1 receptor | Homo sapiens (human) | Potency | 1.8603 | 1 | 2 |
| endonuclease IV | Escherichia coli | Potency | 25.9485 | 1 | 2 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 21.3452 | 10 | 40 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 26.0586 | 2 | 6 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 32.1075 | 9 | 37 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 23.8341 | 2 | 23 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 28.1640 | 4 | 16 |
| eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 22.3872 | 1 | 1 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 20.6665 | 2 | 5 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 14.5149 | 1 | 5 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 26.4698 | 1 | 6 |
| G | Vesicular stomatitis virus | Potency | 15.3699 | 1 | 7 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 11.0007 | 1 | 15 |
| GALC protein | Homo sapiens (human) | Potency | 0.3893 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 11.0007 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 11.0007 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 11.0007 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 11.0007 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 11.0007 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 11.0007 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 11.0007 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 11.0007 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 11.0007 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 11.0007 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 11.0007 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 11.0007 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 11.0007 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 11.0007 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 11.0007 | 1 | 15 |
| geminin | Homo sapiens (human) | Potency | 9.1959 | 3 | 10 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 16.2860 | 2 | 38 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 12.0462 | 2 | 2 |
| GLS protein | Homo sapiens (human) | Potency | 17.9582 | 2 | 9 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 13.5481 | 1 | 3 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 24.6538 | 3 | 13 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 30.0474 | 1 | 2 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 3.6626 | 1 | 1 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 33.4889 | 2 | 3 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 20.5004 | 2 | 32 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 34.8570 | 1 | 4 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 53.3801 | 2 | 6 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 15.3699 | 1 | 7 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 17.9686 | 1 | 4 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 14.2400 | 2 | 6 |
| IDH1 | Homo sapiens (human) | Potency | 19.2532 | 1 | 2 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 3.6626 | 1 | 1 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 15.3699 | 1 | 14 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 7.4570 | 1 | 12 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 12.5893 | 1 | 2 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 12.5893 | 1 | 2 |
| Interferon beta | Homo sapiens (human) | Potency | 13.1053 | 3 | 14 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 13.5502 | 2 | 16 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 17.4183 | 1 | 6 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 21.6989 | 1 | 3 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 9.3546 | 3 | 3 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 32.2382 | 1 | 6 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 18.5496 | 2 | 8 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 17.9831 | 2 | 11 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 1.0096 | 2 | 18 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 11.2202 | 1 | 1 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 11.2202 | 1 | 1 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 18.9272 | 3 | 6 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 1.0000 | 2 | 2 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 7.0795 | 1 | 1 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 22.4564 | 3 | 12 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 22.0274 | 1 | 4 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 15.2803 | 1 | 4 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 17.6096 | 3 | 16 |
| P53 | Homo sapiens (human) | Potency | 70.7946 | 1 | 1 |
| Parkin | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 16.2503 | 1 | 6 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 61.2551 | 1 | 6 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 22.8127 | 2 | 5 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 27.3280 | 4 | 15 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 76.1104 | 1 | 2 |
| PINK1 | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 1.2589 | 1 | 1 |
| polyprotein | Zika virus | Potency | 26.4698 | 1 | 6 |
| polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 14.9225 | 1 | 10 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 8.3160 | 1 | 22 |
| PPM1D protein | Homo sapiens (human) | Potency | 9.1464 | 1 | 4 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 21.1193 | 3 | 18 |
| progesterone receptor | Homo sapiens (human) | Potency | 23.6290 | 3 | 8 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 20.8845 | 2 | 11 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 22.8502 | 1 | 7 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 27.1708 | 3 | 25 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 16.8029 | 3 | 13 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 11.0819 | 2 | 3 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 26.6795 | 1 | 1 |
| shiga toxin 1 B subunit | Escherichia coli O157:H7 | Potency | 0.3177 | 1 | 1 |
| shiga toxin 1 variant A subunit | Escherichia coli O157:H7 | Potency | 0.3177 | 1 | 1 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 39.5994 | 2 | 3 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 39.5994 | 2 | 3 |
| Smad3 | Homo sapiens (human) | Potency | 0.1122 | 1 | 1 |
| snurportin-1 | Homo sapiens (human) | Potency | 3.6626 | 1 | 1 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 16.2384 | 2 | 22 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 14.4809 | 1 | 4 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 0.6310 | 1 | 1 |
| TDP1 protein | Homo sapiens (human) | Potency | 21.2162 | 2 | 61 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 60.3740 | 1 | 2 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 28.8877 | 4 | 11 |
| Thrombopoietin | Homo sapiens (human) | Potency | 11.5543 | 2 | 10 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 27.8198 | 2 | 46 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 95.6570 | 3 | 3 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 25.4026 | 6 | 21 |
| thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 13.4504 | 1 | 1 |
| transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 16.2710 | 1 | 2 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 1.2589 | 1 | 1 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 1.2589 | 1 | 1 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 42.2485 | 1 | 5 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 19.7479 | 2 | 30 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 0.5955 | 1 | 1 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 80.7297 | 1 | 4 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 30.0474 | 1 | 2 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | Ki | 0.0140 | 1 | 3 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | IC50 | 0.1500 | 1 | 1 |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | IC50 | 2.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | IC50 | 1.8888 | 3 | 6 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | Ki | 0.8181 | 17 | 30 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | Ki | 0.4522 | 10 | 12 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | IC50 | 1.4748 | 3 | 5 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | Ki | 0.9696 | 2 | 4 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | IC50 | 0.5870 | 1 | 1 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | Ki | 0.0232 | 1 | 1 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | IC50 | 0.5870 | 1 | 1 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | Ki | 0.0232 | 1 | 1 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | IC50 | 0.1886 | 5 | 15 |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | IC50 | 0.0280 | 1 | 1 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | IC50 | 0.0851 | 11 | 12 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 0.0185 | 47 | 74 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | Ki | 0.0108 | 23 | 29 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | IC50 | 0.6748 | 2 | 12 |
| 5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | IC50 | 0.0280 | 1 | 1 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | IC50 | 0.0355 | 7 | 8 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Ki | 0.3551 | 4 | 14 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | Ki | 0.0136 | 7 | 8 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | IC50 | 0.2300 | 3 | 11 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | IC50 | 0.0328 | 8 | 9 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 0.0351 | 25 | 47 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | Ki | 0.0134 | 10 | 11 |
| 5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | IC50 | 0.0280 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Cavia porcellus (domestic guinea pig) | IC50 | 110.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | Ki | 0.3204 | 3 | 5 |
| 5-hydroxytryptamine receptor 3A | Mus musculus (house mouse) | Ki | 0.0320 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | Ki | 0.0530 | 1 | 1 |
| 5-hydroxytryptamine receptor 3B | Homo sapiens (human) | Ki | 0.3539 | 2 | 4 |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | Ki | 0.0530 | 1 | 1 |
| 5-hydroxytryptamine receptor 3C | Homo sapiens (human) | Ki | 0.3539 | 2 | 4 |
| 5-hydroxytryptamine receptor 3D | Homo sapiens (human) | Ki | 0.3539 | 2 | 4 |
| 5-hydroxytryptamine receptor 3E | Homo sapiens (human) | Ki | 0.3539 | 2 | 4 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | IC50 | 0.2709 | 2 | 9 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | Ki | 0.1465 | 2 | 8 |
| 5-hydroxytryptamine receptor 4 | Homo sapiens (human) | Ki | 0.2239 | 1 | 1 |
| 5-hydroxytryptamine receptor 5A | Homo sapiens (human) | Ki | 1.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | IC50 | 0.5131 | 4 | 9 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | Ki | 0.0619 | 28 | 47 |
| 5-hydroxytryptamine receptor 7 | Cavia porcellus (domestic guinea pig) | IC50 | 37.1250 | 1 | 8 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | Ki | 0.2901 | 30 | 41 |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | Ki | 0.0094 | 2 | 2 |
| Acetylcholinesterase | Electrophorus electricus (electric eel) | IC50 | 22.7200 | 1 | 1 |
| Acetylcholinesterase | Homo sapiens (human) | IC50 | 280.2328 | 10 | 11 |
| Acetylcholinesterase | Homo sapiens (human) | Ki | 3,492.5171 | 6 | 7 |
| Acetylcholinesterase | Bos taurus (cattle) | Ki | 173.2000 | 2 | 2 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | Ki | 0.2190 | 1 | 2 |
| Adenylate cyclase type 1 | Rattus norvegicus (Norway rat) | IC50 | 0.1400 | 1 | 1 |
| Adenylate cyclase type 2 | Rattus norvegicus (Norway rat) | IC50 | 0.1400 | 1 | 1 |
| Adenylate cyclase type 3 | Rattus norvegicus (Norway rat) | IC50 | 0.1400 | 1 | 1 |
| Adenylate cyclase type 4 | Rattus norvegicus (Norway rat) | IC50 | 0.1400 | 1 | 1 |
| Adenylate cyclase type 5 | Rattus norvegicus (Norway rat) | IC50 | 0.1400 | 1 | 1 |
| Adenylate cyclase type 6 | Rattus norvegicus (Norway rat) | IC50 | 0.1400 | 1 | 1 |
| Adenylate cyclase type 8 | Rattus norvegicus (Norway rat) | IC50 | 0.1400 | 1 | 1 |
| Adenylyl cyclase 7 | Rattus norvegicus (Norway rat) | IC50 | 0.1400 | 1 | 1 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | IC50 | 2.3149 | 1 | 7 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | Ki | 2.2955 | 1 | 7 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | IC50 | 0.0110 | 1 | 1 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0567 | 7 | 8 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | Ki | 0.0239 | 10 | 17 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.4566 | 10 | 18 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | IC50 | 0.0110 | 1 | 1 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0567 | 7 | 8 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | Ki | 0.0223 | 9 | 14 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.4601 | 10 | 18 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | IC50 | 0.2250 | 2 | 6 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0567 | 7 | 8 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Ki | 0.0510 | 10 | 19 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.5450 | 8 | 15 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | IC50 | 0.6252 | 1 | 6 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 2.4353 | 2 | 3 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | Ki | 0.2087 | 6 | 16 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0676 | 6 | 8 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | IC50 | 0.8183 | 1 | 6 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 2.4353 | 2 | 3 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | Ki | 0.3139 | 4 | 13 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0702 | 4 | 6 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | IC50 | 0.3078 | 1 | 5 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 2.4353 | 2 | 3 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | Ki | 0.1353 | 5 | 14 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0702 | 4 | 6 |
| Amyloid-beta precursor protein | Homo sapiens (human) | Ki | 0.0059 | 1 | 1 |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | IC50 | 27.0747 | 2 | 7 |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | Ki | 14.3411 | 1 | 5 |
| Aspartate aminotransferase, cytoplasmic | Homo sapiens (human) | IC50 | 5.3900 | 1 | 1 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 6 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | IC50 | 49.2333 | 9 | 9 |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | IC50 | 11.5000 | 4 | 4 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | Ki | 3.6240 | 5 | 5 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | IC50 | 0.3162 | 1 | 1 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | Ki | 0.1800 | 1 | 1 |
| Beta-1 adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 18.0000 | 2 | 2 |
| Beta-1 adrenergic receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.1500 | 1 | 1 |
| Beta-2 adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.1400 | 1 | 1 |
| Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.0159 | 1 | 1 |
| Beta-2 adrenergic receptor | Homo sapiens (human) | Ki | 0.0384 | 2 | 2 |
| Beta-2 adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| Beta-3 adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 224.2825 | 5 | 20 |
| Bile salt export pump | Rattus norvegicus (Norway rat) | IC50 | 196.5000 | 1 | 1 |
| Calcium release-activated calcium channel protein 1 | Homo sapiens (human) | IC50 | 500.0000 | 2 | 2 |
| Calmodulin-1 | Homo sapiens (human) | IC50 | 80.0000 | 2 | 2 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 6 |
| Carboxylic ester hydrolase | Rattus norvegicus (Norway rat) | IC50 | 0.9772 | 1 | 1 |
| Carboxylic ester hydrolase | Equus caballus (horse) | Ki | 0.0200 | 1 | 1 |
| Cholecystokinin receptor type A | Cavia porcellus (domestic guinea pig) | Ki | 0.0600 | 1 | 1 |
| Cholinesterase | Equus caballus (horse) | IC50 | 3.2300 | 2 | 3 |
| Cholinesterase | Homo sapiens (human) | IC50 | 0.8960 | 7 | 7 |
| Cholinesterase | Homo sapiens (human) | Ki | 4,033.3467 | 3 | 3 |
| Cruzipain | Trypanosoma cruzi | IC50 | 212.0000 | 2 | 2 |
| Cytochrome P450 2C19 | Homo sapiens (human) | IC50 | 0.6000 | 1 | 2 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 | 32.0500 | 1 | 2 |
| Cytochrome P450 2C9 | Homo sapiens (human) | Ki | 32.0000 | 1 | 1 |
| Cytochrome P450 2D1 | Rattus norvegicus (Norway rat) | IC50 | 19.9000 | 1 | 1 |
| Cytochrome P450 2D26 | Rattus norvegicus (Norway rat) | IC50 | 2.8000 | 1 | 1 |
| Cytochrome P450 2D3 | Rattus norvegicus (Norway rat) | IC50 | 26.9000 | 1 | 1 |
| Cytochrome P450 2D4 | Rattus norvegicus (Norway rat) | IC50 | 47.2000 | 1 | 1 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 | 2.1309 | 46 | 48 |
| Cytochrome P450 2D6 | Homo sapiens (human) | Ki | 0.0357 | 4 | 4 |
| Cytochrome P450 2J2 | Homo sapiens (human) | IC50 | 32.0500 | 1 | 2 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 39.0000 | 2 | 2 |
| Cytochrome P450 3A4 | Homo sapiens (human) | Ki | 0.0280 | 1 | 6 |
| D | Bos taurus (cattle) | IC50 | 2.7700 | 3 | 3 |
| D | Rattus norvegicus (Norway rat) | IC50 | 1.0016 | 9 | 15 |
| D | Bos taurus (cattle) | Ki | 0.4200 | 8 | 13 |
| D | Rattus norvegicus (Norway rat) | Ki | 0.1865 | 13 | 23 |
| D(1A) dopamine receptor | Homo sapiens (human) | IC50 | 1.0445 | 1 | 4 |
| D(1A) dopamine receptor | Homo sapiens (human) | Ki | 0.1968 | 13 | 23 |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.9554 | 6 | 9 |
| D(1B) dopamine receptor | Homo sapiens (human) | Ki | 0.4890 | 2 | 2 |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.1742 | 2 | 2 |
| D(2) dopamine receptor | Bos taurus (cattle) | IC50 | 1.5250 | 6 | 6 |
| D(2) dopamine receptor | Homo sapiens (human) | IC50 | 1.8999 | 9 | 15 |
| D(2) dopamine receptor | Mus musculus (house mouse) | IC50 | 0.2900 | 1 | 2 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.6653 | 20 | 29 |
| D(2) dopamine receptor | Bos taurus (cattle) | Ki | 0.6900 | 1 | 1 |
| D(2) dopamine receptor | Chlorocebus aethiops (grivet) | Ki | 0.2540 | 2 | 2 |
| D(2) dopamine receptor | Homo sapiens (human) | Ki | 0.0942 | 86 | 113 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.1299 | 26 | 54 |
| D(3) dopamine receptor | Homo sapiens (human) | IC50 | 0.3611 | 2 | 8 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.9554 | 6 | 9 |
| D(3) dopamine receptor | Chlorocebus aethiops (grivet) | Ki | 0.4660 | 1 | 1 |
| D(3) dopamine receptor | Homo sapiens (human) | Ki | 0.3255 | 36 | 54 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.2813 | 5 | 6 |
| D(4) dopamine receptor | Homo sapiens (human) | IC50 | 0.0868 | 12 | 13 |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.9554 | 6 | 9 |
| D(4) dopamine receptor | Homo sapiens (human) | Ki | 0.1752 | 51 | 61 |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.0880 | 5 | 5 |
| Delta-type opioid receptor | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Endothelin receptor type B | Homo sapiens (human) | Ki | 0.0126 | 2 | 2 |
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | Ki | 0.0126 | 1 | 1 |
| Estrogen receptor 1 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| estrogen receptor beta isoform 1 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 2 |
| Gastrin/cholecystokinin type B receptor | Mus musculus (house mouse) | Ki | 0.0038 | 1 | 2 |
| Glucose-6-phosphate 1-dehydrogenase | Homo sapiens (human) | Ki | 497.2000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | IC50 | 0.1380 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | Ki | 3.8500 | 1 | 2 |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | IC50 | 0.1380 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | Ki | 3.8500 | 1 | 2 |
| Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | Ki | 3.8500 | 1 | 2 |
| Glutamate receptor ionotropic, NMDA 2C | Homo sapiens (human) | Ki | 3.8500 | 1 | 2 |
| Glutamate receptor ionotropic, NMDA 2D | Homo sapiens (human) | Ki | 3.8500 | 1 | 2 |
| Glutamate receptor ionotropic, NMDA 3A | Homo sapiens (human) | Ki | 3.8500 | 1 | 2 |
| Glutamate receptor ionotropic, NMDA 3B | Homo sapiens (human) | Ki | 3.8500 | 1 | 2 |
| Histamine H1 receptor | Homo sapiens (human) | IC50 | 11.9469 | 2 | 10 |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0230 | 1 | 2 |
| Histamine H1 receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.0126 | 1 | 2 |
| Histamine H1 receptor | Homo sapiens (human) | Ki | 0.0341 | 12 | 25 |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | Ki | 0.0050 | 1 | 2 |
| Histamine H2 receptor | Homo sapiens (human) | IC50 | 3.0848 | 1 | 5 |
| Histamine H2 receptor | Homo sapiens (human) | Ki | 3.0334 | 1 | 5 |
| Histamine H3 receptor | Homo sapiens (human) | Ki | 0.8155 | 2 | 2 |
| Histamine H4 receptor | Homo sapiens (human) | Ki | 10.8088 | 4 | 4 |
| Histidine-rich protein PFHRP-II | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 325.0000 | 1 | 1 |
| Kappa-type opioid receptor | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Lethal(3)malignant brain tumor-like protein 1 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Lethal(3)malignant brain tumor-like protein 3 | Homo sapiens (human) | IC50 | 54.0000 | 1 | 1 |
| Lethal(3)malignant brain tumor-like protein 4 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| MBT domain-containing protein 1 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Mu-type opioid receptor | Homo sapiens (human) | IC50 | 2.2720 | 1 | 1 |
| Mu-type opioid receptor | Homo sapiens (human) | Ki | 1.6610 | 2 | 2 |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 0.0008 | 1 | 1 |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | IC50 | 38.1000 | 2 | 2 |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 | 118.4667 | 1 | 6 |
| Muscarinic acetylcholine receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.0657 | 2 | 2 |
| Muscarinic acetylcholine receptor DM1 | Drosophila melanogaster (fruit fly) | Ki | 1.2605 | 2 | 6 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | IC50 | 0.1663 | 21 | 27 |
| Muscarinic acetylcholine receptor M1 | Mus musculus (house mouse) | IC50 | 0.7500 | 1 | 3 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | IC50 | 0.5693 | 38 | 53 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | Ki | 0.4565 | 36 | 49 |
| Muscarinic acetylcholine receptor M1 | Mus musculus (house mouse) | Ki | 0.1072 | 1 | 1 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Ki | 0.0403 | 10 | 15 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | IC50 | 0.2611 | 13 | 18 |
| Muscarinic acetylcholine receptor M2 | Mus musculus (house mouse) | IC50 | 0.5100 | 3 | 6 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | IC50 | 0.6029 | 40 | 52 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | Ki | 0.2158 | 28 | 38 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | Ki | 1.1574 | 12 | 17 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | IC50 | 0.1591 | 16 | 24 |
| Muscarinic acetylcholine receptor M3 | Mus musculus (house mouse) | IC50 | 0.7500 | 1 | 3 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | IC50 | 0.5973 | 39 | 51 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | Ki | 0.4169 | 29 | 42 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | Ki | 0.2152 | 9 | 12 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | IC50 | 0.3402 | 13 | 21 |
| Muscarinic acetylcholine receptor M4 | Mus musculus (house mouse) | IC50 | 0.7500 | 1 | 3 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | IC50 | 0.5972 | 38 | 50 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | Ki | 0.2222 | 18 | 30 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | Ki | 0.0799 | 7 | 10 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | IC50 | 0.1435 | 9 | 17 |
| Muscarinic acetylcholine receptor M5 | Mus musculus (house mouse) | IC50 | 0.7500 | 1 | 3 |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | IC50 | 0.5972 | 38 | 50 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | Ki | 0.3171 | 15 | 25 |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | Ki | 0.0626 | 4 | 6 |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | IC50 | 31.2538 | 1 | 6 |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | Ki | 14.3411 | 1 | 5 |
| Pleiotropic ABC efflux transporter of multiple drugs | Saccharomyces cerevisiae S288C | IC50 | 6.8000 | 1 | 2 |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | IC50 | 2.7680 | 1 | 1 |
| Potassium voltage-gated channel subfamily A member 5 | Homo sapiens (human) | IC50 | 7.3000 | 1 | 1 |
| Potassium voltage-gated channel subfamily D member 2 | Rattus norvegicus (Norway rat) | IC50 | 2.2000 | 1 | 1 |
| Potassium voltage-gated channel subfamily D member 3 | Homo sapiens (human) | IC50 | 12.5892 | 2 | 2 |
| Potassium voltage-gated channel subfamily E member 1 | Homo sapiens (human) | IC50 | 49.6927 | 2 | 2 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 | 5.9232 | 21 | 51 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | Ki | 15.4170 | 6 | 12 |
| Potassium voltage-gated channel subfamily KQT member 1 | Homo sapiens (human) | IC50 | 49.6927 | 2 | 2 |
| Protein orai-2 | Homo sapiens (human) | IC50 | 500.0000 | 2 | 2 |
| Protein orai-3 | Homo sapiens (human) | IC50 | 500.0000 | 2 | 2 |
| Ras-related C3 botulinum toxin substrate 1 | Homo sapiens (human) | IC50 | 95.0000 | 1 | 1 |
| Ras-related C3 botulinum toxin substrate 1 | Mus musculus (house mouse) | IC50 | 6.3000 | 2 | 2 |
| Sigma intracellular receptor 2 | Homo sapiens (human) | Ki | 0.0251 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | IC50 | 0.0748 | 1 | 5 |
| Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | Ki | 0.0090 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | Ki | 1.2382 | 3 | 7 |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | IC50 | 17.3362 | 6 | 6 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | IC50 | 2.9529 | 1 | 4 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | Ki | 0.2392 | 4 | 5 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | IC50 | 0.8015 | 1 | 3 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | Ki | 0.3904 | 2 | 5 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | IC50 | 2.3149 | 1 | 7 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | Ki | 2.0091 | 2 | 8 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | IC50 | 0.6426 | 1 | 5 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 2.3044 | 3 | 9 |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | Ki | 0.0210 | 1 | 1 |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | IC50 | 18.3500 | 2 | 2 |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | Ki | 10.3000 | 2 | 2 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | IC50 | 47.6400 | 5 | 8 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | Ki | 17.5000 | 1 | 1 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | IC50 | 2.5000 | 1 | 1 |
| Solute carrier family 22 member 2 | Rattus norvegicus (Norway rat) | IC50 | 23.3000 | 2 | 2 |
| Solute carrier family 22 member 2 | Rattus norvegicus (Norway rat) | Ki | 19.1000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1A1 | Rattus norvegicus (Norway rat) | Ki | 9.2700 | 1 | 1 |
| Solute carrier organic anion transporter family member 1A4 | Rattus norvegicus (Norway rat) | Ki | 120.0000 | 1 | 1 |
| Testosterone 17-beta-dehydrogenase 3 | Rattus norvegicus (Norway rat) | IC50 | 0.0001 | 1 | 1 |
| Transporter | Rattus norvegicus (Norway rat) | Ki | 0.8186 | 2 | 5 |
| Trypanothione reductase | Trypanosoma cruzi | IC50 | 108.0000 | 1 | 1 |
| Trypanothione reductase | Trypanosoma cruzi | Ki | 59.1000 | 1 | 1 |
| UDP-glucuronosyltransferase 1-6 | Homo sapiens (human) | IC50 | 273.2000 | 1 | 5 |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | IC50 | 273.2000 | 1 | 5 |
| UDP-glucuronosyltransferase 1A4 | Homo sapiens (human) | IC50 | 273.2000 | 1 | 5 |
| UDP-glucuronosyltransferase 2B10 | Homo sapiens (human) | IC50 | 273.2000 | 1 | 5 |
| UDP-glucuronosyltransferase 2B7 | Homo sapiens (human) | IC50 | 273.2000 | 1 | 5 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Cavia porcellus (domestic guinea pig) | IC50 | 16.6000 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | IC50 | 327.9658 | 5 | 5 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Rattus norvegicus (Norway rat) | Ki | 1.0800 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Rattus norvegicus (Norway rat) | Ki | 1.0800 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | IC50 | 5.0000 | 2 | 2 |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | IC50 | 5.0000 | 2 | 2 |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | IC50 | 5.0000 | 2 | 2 |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Rattus norvegicus (Norway rat) | Ki | 1.0800 | 1 | 1 |